Skip to main content

Canada authorizes AstraZeneca's drug for COVID prevention

Share

Canada on Thursday authorized British drugmaker AstraZeneca Plc's AZN.L antibody-based therapy for preventing COVID-19 infections, giving itself another weapon against the disease as cases rise in the country.

Health Canada has cleared the drug - Evusheld - for use in individuals aged 12 years and older who are immune compromised and unlikely to mount an adequate immune response to COVID-19 vaccination or for whom COVID-19 vaccination is not recommended.

While vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in case of an infection.

The therapy has already been authorized in the United States and its use has also been recommended by the European Medicines Agency.

CTVNews.ca Top Stories

New weight-loss drug Wegovy not a 'magic bullet,' doctor warns

As Wegovy becomes available to Canadians starting Monday, a medical expert is cautioning patients wanting to use the drug to lose weight that no medication is a ''magic bullet,' and the new medication is meant particularly for people who meet certain criteria related to obesity and weight.

Drew Carey is never quitting 'The Price Is Right'

Drew Carey took over as host of 'The Price Is Right' and hopes he’s there for life. 'I'm not going anywhere,' he told 'Entertainment Tonight' of the job he took over from longtime host Bob Barker in 2007.

Local Spotlight

Stay Connected